1239964-01-2

Upstream product

• 1017478-92-0 3-(3-chlorophenyl)-3-methylbutan-2-one 
• 1239963-99-5 3-(3-chlorophenyl)-3-methylbutan-2-ol 
• 1225521-01-6 2-(3-chlorophenyl)-2-methylpropanal 
• 64798-33-0 2-(3-chloro-phenyl)-2-methyl-propionitrile 
• 1239964-00-1 2-chloro-4-(2-methyl-3-oxobutan-2-yl)benzene-1-sulfonyl chloride 

Downstream Products

• 1239964-02-3 4-(4-bromo-2-methyl-3-oxobutan-2-yl)-2-chlorobenzenesulfonamide 
• 1239964-03-4 4-(4-azido-2-methyl-3-oxobutan-2-yl)-2-chlorobenzenesulfonamide 
• 1239964-04-5 4-(4-amino-2-methyl-3-oxobutan-2-yl)-2-chlorobenzenesulfonamide hydrochloride 
• 1239964-05-6 2-chloro-4-(4-(3-(4-fluoro-3-methoxyphenyl)thioureido)-2-methyl-3-oxobutan-2-yl)benzenesulfonamide 
• 1239963-98-4 2-chloro-4-(2-(1-(4-fluoro-3-methoxyphenyl)-2-mercapto-1H-imidazol-5-yl)propan-2-yl)benzenesulfonamide 

Relevant academic research and scientific papers

TGR5 AGONISTS

TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY

The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise